As of May 23, 2025, Xphyto Therapeutics Corp (XPHY.CN) reports a EV/EBITDA of -3.61.
EV/EBITDA evaluates a company's total value relative to its earnings before interest, taxes, depreciation, and amortization, useful for comparing firms with different capital structures.
Comparing Xphyto Therapeutics Corp's EV/EBITDA to Peers
To better understand Xphyto Therapeutics Corp's position, it's useful to compare its EV/EBITDA against industry peers. Below are selected comparisons:
| Company | EV/EBITDA |
|---|---|
| Xphyto Therapeutics Corp (XPHY.CN) | -3.61 |
| Rubicon Organics Inc (ROMJ.V) | 11.36 |
| Next Green Wave Holdings Inc (NGW.CN) | 10.52 |
| Medicine Man Technologies Inc (SHWZ) | 6.23 |
| Prophase Labs Inc (PRPH) | 4.78 |
| Evoke Pharma Inc (EVOK) | 0.59 |
Compared to its competitors, Xphyto Therapeutics Corp's EV/EBITDA is among the lowest compared to peers, which may indicate undervaluation or market concerns about future performance.